


Highlights of This Issue 1359

PERSPECTIVE

- 1361** Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development
 Philip M. Tedeschi, Alexei Vazquez, John E. Kerrigan, and Joseph R. Bertino

CELL DEATH AND SURVIVAL

- 1367** Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells
 Ping Fan, Heather E. Cunliffe, Philipp Y. Maximov, Fadeke A. Agboke, Russell E. McDaniel, Xiaojun Zou, Pilar Ramos, Megan L. Russell, and V. Craig Jordan
- 1377** mTORC2 Balances AKT Activation and eIF2 α Serine 51 Phosphorylation to Promote Survival under Stress
 Clara Tenkerian, Jothilatha Krishnamoorthy, Zineb Mounir, Urszula Kazimierczak, Arkady Khoutorsky, Kirk A. Staschke, Arnold S. Kristof, Shuo Wang, Maria Hatzoglou, and Antonis E. Koromilas

DNA DAMAGE AND REPAIR

- 1389** YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors
 Gregory C. Stachelek, Elizabeth Peterson-Roth, Yanfeng Liu, Rafael J. Fernandez III, Luke R.G. Pike, Jack M. Qian, Laura Abriola, Denton Hoyer, William Hungerford, Janie Merkel, and Peter M. Glazer

ONCOGENES AND TUMOR SUPPRESSORS

- 1398** Tumor Suppressor Activity of Klotho in Breast Cancer Is Revealed by Structure–Function Analysis
 Hagai Ligumsky, Tami Rubinek, Keren Merenbakh-Lamin, Adva Yehekel, Rotem Sertchook, Shiri Shahmoon, Sarit Aviell-Ronen, and Ido Wolf
- 1408** Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway
 Gregory R. Kardos, Hannah C. Wastyk, and Gavin P. Robertson
- 1421** Decreased eIF3e Expression Can Mediate Epithelial-to-Mesenchymal Transition through Activation of the TGF β Signaling Pathway
 Guillaume Desnoyers, Laura D. Frost, Lynn Courteau, Michael L. Wall, and Stephen M. Lewis

SIGNAL TRANSDUCTION

- 1431** Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer
 Neil E. Martin, Travis Gerke, Jennifer A. Sinnott, Edward C. Stack, Ove Andrén, Swen-Olof Andersson, Jan-Erik Johansson, Michelangelo Fiorentino, Stephen Finn, Giuseppe Fedele, Meir Stampfer, Philip W. Kantoff, Lorelei A. Mucci, and Massimo Loda


CORRECTION

- 1441** Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma

Table of Contents

ABOUT THE COVER

The cover image shows a comprehensive look at four immunohistochemical markers of PI3K activation in prostate cancer. Martin and colleagues sought to define a combined "score" of activation according to PTEN, pAKT, pS6 and stathmin staining. Here the authors show individual tumors ranked according to this four-marker score as well as how this relates to clinical and pathologic features including Ki67, TUNEL, age at diagnosis, lethal outcome, and Gleason score. Please see the article by Martin and colleagues (beginning on page 1431) for more information.



Molecular Cancer Research

13 (10)

Mol Cancer Res 2015;13:1359-1441.

Updated version Access the most recent version of this article at:
<http://mcr.aacrjournals.org/content/13/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mcr.aacrjournals.org/content/13/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.